Loading
companiesCompany
DELFI Diagnostics
Fragmentomics company whose FirstLook Lung blood test aims to raise lung-cancer screening uptake; first randomised clinical-utility data in 2026.
Overview
FirstLook Lung (launched 2023) analyses cfDNA fragmentation patterns to identify who should proceed to low-dose CT. The L301 FIRSTLUNG cluster-randomised trial (NCT06145750) was presented as a late-breaker at ATS 2026; AACR 2026 showed whole-genome cfDNA advances in detection and monitoring. Johns Hopkins spin-out.
Similar pages
- CompanyPersonalis (Tempus)
Shares Push residual disease detection a hundredfold deeper with whole-genome methods, Liquid biopsy (ctDNA).
- PersonNickolas Papadopoulos
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
- TrialMERMAID-1
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- Key paperPhylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, The hardest cancers are found late, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- TrialMERMAID-2
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- PersonSarah-Jane Dawson
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
- IdeaTrack clones in blood with methylation patterns instead of mutations
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).
- PersonNitzan Rosenfeld
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA).